A phase I, randomized, placebo controlled, double blind dose escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single intravenous dose of PF-04360365 in adults with mild to moderate Alzheimer's disease.

Trial Profile

A phase I, randomized, placebo controlled, double blind dose escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single intravenous dose of PF-04360365 in adults with mild to moderate Alzheimer's disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Ponezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jul 2010 Results presented at the International Conference on Alzheimer's Disease and Related Disorders in July 2010 (Abstract O3-07-05), according to a Intellect Neurosciences media release.
    • 10 Jul 2010 Results presented at the International Conference on Alzheimer's Disease and Related Disorders in July 2010
    • 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top